![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Biophysics Section, Department of Biological Sciences, The Blackett Laboratory, Imperial College London, United Kingdom
Nitrous oxide, xenon, and cyclopropane are anesthetic gases that have a distinct pharmacological profile. Whereas the molecular basis for their anesthetic actions remains unclear, they behave very differently to most other general anesthetics in that they have little or no effect on GABAA receptors, yet strongly inhibit the N-methyl-D-aspartate subtype of glutamate receptors. Here we show that certain members of the two-pore-domain K+ channel superfamily may represent an important new target for these gaseous anesthetics. TREK-1 is markedly activated by clinically relevant concentrations of nitrous oxide, xenon, and cyclopropane. In contrast, TASK-3, a member of this family that is very sensitive to volatile anesthetics, such as halothane, is insensitive to the anesthetic gases. We demonstrate that the C-terminal cytoplasmic domain is not an absolute requirement for the actions of the gases, although it clearly plays an important modulatory role. Finally, we show that Glu306, an amino acid that has previously been found to be important in the modulation of TREK-1 by arachidonic acid, membrane stretch and internal pH, is critical for the activating effects of the anesthetic gases.
Address correspondence to: Nicholas P. Franks, Biophysics Section, Department of Biological Sciences, The Blackett Laboratory, Imperial College London, London SW7 2AZ, United Kingdom. E-mail: n.franks{at}imperial.ac.uk
This article has been cited by other articles:
|
|
 |
|
  S. Rex, P. T. Meyer, J.-H. Baumert, R. Rossaint, M. Fries, U. Bull, and W. M. Schaefer Positron emission tomography study of regional cerebral blood flow and flow-metabolism coupling during general anaesthesia with xenon in humans Br. J. Anaesth., May 1, 2008; 100(5): 667 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. David, B. Haelewyn, C. Rouillon, M. Lecoq, L. Chazalviel, G. Apiou, J.-J. Risso, M. Lemaire, and J. H. Abraini Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia FASEB J, April 1, 2008; 22(4): 1275 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hobbs, M. Thoresen, A. Tucker, K. Aquilina, E. Chakkarapani, and J. Dingley Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia Stroke, April 1, 2008; 39(4): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Salmi, R. M. Laitio, S. Aalto, A. T. Maksimow, J. W. Langsjo, K. K. Kaisti, R. Aantaa, V. Oikonen, L. Metsahonkala, K. Nagren, et al. Xenon Does Not Affect {gamma}-Aminobutyric Acid Type A Receptor Binding in Humans Anesth. Analg., January 1, 2008; 106(1): 129 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Magra, S. Hughes, A. J. El Haj, and N. Maffulli VOCCs and TREK-1 ion channel expression in human tenocytes Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1053 - C1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Colloc'h, J. Sopkova-de Oliveira Santos, P. Retailleau, D. Vivares, F. Bonnete, B. Langlois d'Estainto, B. Gallois, A. Brisson, J.-J. Risso, M. Lemaire, et al. Protein Crystallography under Xenon and Nitrous Oxide Pressure: Comparison with In Vivo Pharmacology Studies and Implications for the Mechanism of Inhaled Anesthetic Action Biophys. J., January 1, 2007; 92(1): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C.E. Francis, C. Hohne, A. Klein, B. Donaubauer, U. Kaisers, and W. Boemke Endothelin-a receptor blockade does not debilitate the cardiovascular and hormonal adaptation to xenon or isoflurane anesthesia in dogs. Experimental Biology and Medicine, June 1, 2006; 231(6): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dinse, K. J. Fohr, M. Georgieff, C. Beyer, A. Bulling, and H. U. Weigt Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones Br. J. Anaesth., April 1, 2005; 94(4): 479 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Sanders, D. Ma, and M. Maze Xenon: elemental anaesthesia in clinical practice Br. Med. Bull., February 22, 2005; 71(1): 115 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chemin, A. Patel, F. Duprat, M. Zanzouri, M. Lazdunski, and E. Honore Lysophosphatidic Acid-operated K+ Channels J. Biol. Chem., February 11, 2005; 280(6): 4415 - 4421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Caley, M. Gruss, and N. P. Franks The effects of hypoxia on the modulation of human TREK-1 potassium channels J. Physiol., January 1, 2005; 562(1): 205 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Buckler and E. Honore The lipid-activated two-pore domain K+ channel TREK-1 is resistant to hypoxia: implication for ischaemic neuroprotection J. Physiol., January 1, 2005; 562(1): 213 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gruss, A. Mathie, W. R. Lieb, and N. P. Franks The Two-Pore-Domain K+ Channels TREK-1 and TASK-3 Are Differentially Modulated by Copper and Zinc Mol. Pharmacol., September 1, 2004; 66(3): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nagele, L. B. Metz, and C. M. Crowder Nitrous oxide (N2O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans PNAS, June 8, 2004; 101(23): 8791 - 8796. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
